Lucentis

Lucentis - General Information

Lucentis is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Lucentis binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Lucentis has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

Pharmacology of Lucentis

Lucentis is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Lucentis binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A).

Lucentis for patients

In the days following LUCENTIS administration, patients are at risk of developing endophthalmitis. If the eye becomes red, sensitive to light, painful, or develops a change in vision, the patient should seek immediate care from an ophthalmologist.

Lucentis Interactions

Drug interaction studies have not been conducted with LUCENTIS.

LUCENTIS intravitreal injection has been used adjunctively with verteporfin photodynamic therapy (PDT). Twelve of 105 (11%) patients developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (±2 days) after verteporfin PDT.

Lucentis Contraindications

Ocular or Periocular Infections

LUCENTIS is contraindicated in patients with ocular or periocular infections.

Hypersensitivity

LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.

Additional information about Lucentis

Lucentis Indication: For the treatment of patients with neovascular (wet) age-related macular degeneration.
Mechanism Of Action: Lucentis binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and is thought to contribute to the progression of the neovascular form of age-related macular degeneration (AMD). The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Ranibizumab
Synonyms: Not Available
Drug Category: Not Available
Drug Type: Biotech; Approved

Other Brand Names containing Ranibizumab: Lucentis;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Approximately 3 days
Dosage Forms of Lucentis: Solution Intravitreal
Chemical IUPAC Name: Not Available
Chemical Formula: C2158H3282N562O681S12
Ranibizumab on Wikipedia: https://en.wikipedia.org/wiki/Ranibizumab
Organisms Affected: Humans and other mammals